A Randomized, Placebo-Controlled, Double-Blind, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of RCN3028 in Treatment of Drug-Induced Moderate to Severe Vasomotor Symptoms in Breast Cancer Subjects
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 10
- 试验地点
- 4
- 主要终点
- Mean change in severity of moderate to severe VMS
研究概览
简要总结
Due to the fact that majority of breast cancers are estrogen-receptor and/or progesterone receptor positive, tamoxifen and aromatase inhibitors (AIs) are among the mainstay therapies to treat breast cancer. Prior clinical studies of tamoxifen suggested that up to 80 % of patients experienced hot flashes during therapy with tamoxifen, and 30 % defined their symptoms as severe. Despite the high efficacy of tamoxifen, the harmful side effects have been identified in previous studies as a significant reason for not persisting with the treatment in 16 - 30 % of breast cancer patients.
The primary purpose of this study is to determine if RCN3028 is effective and safe in the treatment of moderate to severe vasomotor symptoms associated. In accordance with the latest FDA guidance study participants will have a minimum of 7 moderate to sever hot flashes per day, or 50 per week at baseline.
详细描述
Hot flashes are the most common symptom of menopause and affect almost 75% of menopausal women. Clinical evidence indicates potent antagonists of 5-HT2a are more likely to cause hypothermia. Risperidone is a potent 5-HT2a and a dopamine D2 receptor antagonist and is proposed to have effect on reduction of hot flashes through its dopaminergic and serotonergic antagonism.
Breast cancer is one of the most common cancers in women, according to the cancer registration report of the Ministry of Health and Welfare (MOHW), in 2014, up to 11,976 women suffered from breast cancer, which meant 33 women suffered from breast cancer daily. Recent epidemiology further disclosed that the incidence of breast cancer was top-ranked (70.74 per 100,000) among cancers of Taiwanese women in 2014.
Due to the fact that majority of breast cancers are estrogen-receptor and/or progesterone receptor positive, tamoxifen and aromatase inhibitors (AIs) are among the mainstay therapies to treat breast cancer. Prior clinical studies of tamoxifen suggested that up to 80 % of patients experienced hot flashes during therapy with tamoxifen, and 30 % defined their symptoms as severe. Despite the high efficacy of tamoxifen, the harmful side effects have been identified in previous studies as a significant reason for not persisting with the treatment in 16 - 30 % of breast cancer patients.
The primary purpose of this study is to determine if RCN3028 is effective and safe in the treatment of moderate to severe vasomotor symptoms associated. In accordance with the latest FDA guidance study participants will have a minimum of 7 moderate to sever hot flashes per day, or 50 per week at baseline.
With recent advances of treatment modalities, more than 80% of women with a newly diagnosed breast cancer are expected to survive their disease for 5 years or more. One of the most common complaints was hot flashes induced by the treatment of breast cancer (i.e., tamoxifen induced hot flashes).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female subjects (aged 20 years or order) with confirmed diagnosis of breast cancer who have completed chemotherapy and radiotherapy, and are on a stable dose of tamoxifen or aromatase inhibitors (AIs) for at least 8 weeks at baseline and will maintain the same treatment regimen and dose throughout the study.
- •Reported 7 or more moderate to severe hot flashes per day (average) or 50 moderate to severe hot flashes per week at baseline.
- •Screening laboratory values for hematopoietic, hepatic, and renal functions are within the following ranges:
- •Hematopoietic : Absolute neutrophil count ≥ 1,500/mm3、Platelet count ≥ 100,000/mm3
- •Hepatic : Glutamic Oxaloacetic Transaminase/Glutamic Pyruvic Transaminase ≤ 3 times upper limit of normal (ULN)、Bilirubin ≤ 1.5 times ULN
- •Renal : Creatinine ≤ 1.5 times ULN
- •Having Eastern Collaborative Oncology Group (ECOG) Performance Status of ≤
- •Ability to understand and follow the instructions of the investigator, including completion of the study procedures as described in the protocol (i.e., VMS episode event log).
- •Able and willing to provide written informed consent.
排除标准
- •Subjects are pregnant or breastfeeding.
- •Female subjects who have childbearing potential, but they are not willing to use effective contraceptive methods during study period and for 1 week afterward.
- •Subjects who have multiple primary cancers (except for completely resected basal cell cancer, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer or any other cancer from which the patient has been recurrence-free for at least 5 years).
- •Subjects who have inoperable breast cancer (Stage IIIB/IIIC/IV).
- •Subjects who have the following medical history: myocardial infarction, congestive heart failure, significant ischemic or valvular heart disease, clinically active interstitial lung disease.
- •Subjects who have systolic blood pressure (BP) outside the range 100 to 150 mmHg, diastolic BP outside the range 60 to 90 mmHg, and/or heart rate outside the range 50 to 100 bpm at baseline.
- •Subjects who had received treatment for hypotension within 30 days prior to screening visit.
- •Subjects who have uncontrolled hyperglycemia, HbA1c ≥ 7% at baseline.
- •Subjects who have clinical significant conditions such as acute myocardial infarction or stroke with 6 months of randomization.
- •Subjects who have a history of Parkinson's disease.
- •Subjects are taking risperidone in the 30 days prior to screening visit.
- •Subjects who had participated in another clinical trial and received an investigational drug within 30 days prior to screening visit.
- •Subjects having a known history of allergic reaction, hypersensitivity or clinically significant intolerance to ingredients of the study drug.
- •Subjects with a current drug or alcohol abuse problem as judged by the investigator.
- •Subjects who are considered unreliable as to medication compliance or adherence to scheduled appointments or for other reasons are felt to be inappropriate for inclusion in the study as determined by the investigators.
- •Subjects who use Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), within 4 weeks prior to screening visit.
- •Subjects who use herbal or dietary supplements, including black cohosh, soy, phytoestrogens or over the counter agents known to possibly be effective for the treatment of vasomotor symptoms within 2 weeks prior to baseline.
- •Subjects who have serious, unstable, or clinically significant medical or psychological conditions, which, in the opinion of the investigator(s), would compromise the subject's participation in the study.
研究组 & 干预措施
I placebo capsule
Subjects will be enrolled to about 14-days of placebo-run-in period.
Other Names:
RCN3028 placebo
干预措施: Placebo (Drug)
II RCN3028 0.8 mg capsule
Subjects will be enrolled to about 14-days of placebo-run-in period. Treatment started at 0.4 mg, titrated to 0.8 mg for maintenance phase.
Other Names:
RCN3028 0.8 mg capsule
干预措施: 0.8 mg RCN3028 (Drug)
结局指标
主要结局
Mean change in severity of moderate to severe VMS
时间窗: 4, 12 weeks
Mean change in severity score of moderate to severe VMS from baseline to weeks 4 and week 12. The severity score for VMS for each subject is calculated as the sum of 2 times the number of moderate VMS, plus 3 times the number of severe VMS, divided by the total number of moderate and severe VMS.
Mean change in frequency of moderate to severe VMS
时间窗: 4, 12 weeks
Mean change in frequency numbers of moderate to severe VMS(Vasomotor Symptoms) from baseline to weeks 4 and week 12. The VMS episode event log recorded the frequency of hot flashes per day, such mild, moderate, severe, nighttime awakening number.
次要结局
- Menopause Specific Quality of Life Questionnaire(12 weeks)
- Subject's and Physician's Global Assessment(12 weeks)
- Change from baseline in the number of mild, moderate, and severe hot flashes.(12 weeks)
- Change from baseline in the number of nighttime awakenings because of hot flashes.(12 weeks)
- The 50%, 75% and 100% responder rates(12 weeks)
- The time to onset of efficacy(12 weeks)
- Frequencies(number and percentage) of subjects with treatment-emergent AEs (TEAEs)(12 weeks)
- Change from baseline in weekly weighted severity score.(12 weeks)